Drug Profile


Alternative Names: AZD-0914; ETX-0914

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; National Institute of Allergy and Infectious Diseases
  • Class Antibacterials; Ketones; Oxazines; Oxazolidinones; Pyrimidines; Quinolines; Spiro compounds
  • Mechanism of Action DNA gyrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gonorrhoea

Most Recent Events

  • 06 Sep 2017 Zoliflodacin is still in phase II development for Gonorrhoea in USA (Entasis Therapeutics pipeline, September 2017)
  • 06 Jul 2017 Entasis Therapeutics and Global Antibiotic Research and Development Partnership agree to co-develop and co-promote Zoliflodacin in South Africa, USA, Thailand and World for Gonorrhoea
  • 26 Oct 2016 Efficacy data from a phase II trial in Gonorrhea presented at the IDWeek 2016 (IDW-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top